Identification of CD101 in Glioma: A Novel Prognostic Indicator Expressed on M2 Macrophages.

ABSTRACT: Glioma represents the most common primary intracranial malignancy worldwide, with low overall survival rates and limited therapeutic options. The protein CD101, mainly expressed on several immune cells, has been demonstrated to exert potent effects on blunting T cell immune responses across infectious and autoimmunity diseases. Nevertheless, the prognostic value of CD101 expression and its role in the immune microenvironment of various malignancies currently remains elusive. Herein, by adopting bioinformatics methodology, we comprehensively illustrated the potential function and predictive value of CD101 in stratifying clinical prognosis among patients with glioma, for which a high CD101 level predicted an unfavorable clinical outcome in glioma patients. Results from enrichment analyses ma

SUBMITTER: Liu Y 

PROVIDER: S-EPMC8957828 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature